Prolonged Enoxaparin in Primary Percutaneous Coronary Intervention

PHASE4CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

June 28, 2018

Primary Completion Date

May 1, 2020

Study Completion Date

May 1, 2020

Conditions
Myocardial Infarction
Interventions
DRUG

Enoxaparin

Patients allocated to the experimental arm will receive a parenteral (IA/IV) bolus dose of enoxaparin (0.75 mg/kg) pre PPCI followed by an infusion of 0.75 mg/kg over a 6-hour period to be started as soon as possible when PPCI starts.

Trial Locations (1)

S5 7AU

Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Medical Research Council

OTHER_GOV

lead

Sheffield Teaching Hospitals NHS Foundation Trust

OTHER